Table 3 Crude and adjusted hazard rate ratios of mortality during and after tuberculosis treatment among persons who initiated treatment for RR or M/XDR TB with and without pre-existing comorbidities in Georgia, 2009–2017 (N = 1032).

From: HIV co-infection increases the risk of post-tuberculosis mortality among persons who initiated treatment for drug-resistant tuberculosis

Comorbidities

Study outcomes

Tuberculosis mortality during treatment

(n = 34)

Tuberculosis mortality after treatment

(n = 87)

cHR (95%CI)

aHRa (95%CI)

cHR (95%CI)

aHRa (95%CI)

HIV co-infection

 No

Reference

Reference

Reference

Reference

 Yes

9.33 (3.92–22.23)

11.52 (4.57–29.06)

4.56 (2.27–9.15)

3.74 (1.77–7.91)

 Missing

4.10 (1.80–9.37)

3.70 (1.48–9.27)

1.11 (0.57–2.17)

1.05 (0.53–2.12)

Hyperglycemiab

 No

Reference

 

Reference

 

 Yes

0.37 (0.11–1.24)

 

1.60 (0.98–2.60)

 

 Missing

1.47 (0.70–3.06)

 

1.24 (0.72–2.14)

 

Diabetes status

 No diabetes

Reference

Reference

Reference

Reference

 Pre-diabetes

NA

NA

1.47 (0.79–2.75)

1.48 (0.78–2.78)

 Diabetes

0.76 (0.23–2.55)

0.75 (0.19–3.00)

1.73 (0.94–3.18)

1.06 (0.53–2.12)

 Missing

1.47 (0.70–3.06)

1.72 (0.79–3.75)

1.24 (0.72–2.14)

1.45 (0.82–2.59)

HCV co-infection

 No

Reference

Reference

Reference

Reference

 Yes

1.40 (0.55–3.56)

0.93 (0.33–2.66)

1.58 (0.92–2.73)

1.21 (0.68–2.15)

 Missing

1.39 (0.65–2.96)

1.26 (0.55–2.87)

1.12 (0.68–1.85)

0.90 (0.53–1.55)

Any primary comorbidityc

 No

Reference

 

Reference

 

 Yes

1.42 (0.72–2.80)

 

2.03 (1.33–3.10)

 
  1. Areas shaded in grey indicate that variables were not included in the final models, and thus, adjusted hazard rate ratios were not obtained.
  2. Bold indicates that the finding is statistically significant at α = 0.05.
  3. aHR: adjusted hazard rate ratios; cHR: crude hazard rate ratios; CI: confidence interval; HCV: hepatitis C virus; HIV: human immunodeficiency virus.
  4. aModel was adjusted for HIV-coinfection, diabetes status, HCV co-infection, age, gender, cavitary disease, type of drug resistance, smoking, and BMI at TB treatment initiation (fully-adjusted model).
  5. bIncluded individuals with pre-diabetes and diabetes.
  6. cAny comorbidity was defined as the presence of either hyperglycemia, hepatitis C, or HIV co-infection.
Back to article page